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Purpose: Very scarce information has been published to date with the combination of ABC/3TC/NVP but it is currently being
used in clinical practice in Spain and Portugal. Our aim was to present the clinical experience with this regimen in a cohort of
adult HIV-infected antiretroviral (ARV)-naı¨ve patients.
Methods: Retrospective, multicentre, cohort study. Consecutive adult HIV-infected ARV-naı¨ve HLA-B*5701-negative patients,
who started ABC/3TC/NVP between 2005-2013, with at least one follow-up visit, were included. Demographic, clinical and
laboratory variables were assessed at baseline, month 1, and every threefour months thereafter. The primary end point was
HIV-1 viral load (VL)B40 c/mL at 48 weeks. Data were analyzed by intent-to-treat (ITT) (switchfailure, and missingfailure)
and on treatment (OT) analyses.
Results: 78 patients were included. Median follow up was 26 (0.1-84) months. 86% were male, median age 41 (23-69) years, 9%
had AIDS, 8% were HCV, baseline CD4 was 275 (10-724) cells/mL and median VL 4.58 (3.02-6.92) log. After 48 weeks, VL
wasB40 c/mL in 89.8% (OT), 79.7% (MF) and 65.4% (SF) and at 96 weeks in 88.5%, 78.9% and 61.6%, respectively. CD4
increased 246 (pB0.001) and 292 (pB0.001) cells/uL after 48 and 96 weeks, respectively. One or more drugs of the
regimen were discontinued in 33 (42.3%) patients. In 15 (19.2%) patients (13 NVP, 2 ABC/3TC) therapy was stopped due to
toxicity after a median of one month (in only two cases after six months of follow up): 80% of them had rash/liver toxicity. Six
(7.7%) patients discontinued ART due to virologic failure, five (6.4%) because of other reasons and seven (9%) were lost to
follow-up. ALT but not AST significantly increased (0.07 ukat/L at 96 weeks, p0.033). A significant increase of 25%, 26% and
42% in total cholesterol, LDLc and HDLc, respectively, and a significant decrease in TC/HDL ratio (6%, p0.008) was observed
after 96 weeks.
Conclusions: Despite a considerable proportion of patients had to stop therapy due to toxicity (most associated with NVP), those
initially tolerating this regimen presented a high virologic and immunologic response after 96 weeks, as well as a favourable lipid
profile. ABC/3TC/NVP may be a suitable alternative first regimen, mainly in countries with economic constraints.
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